How to buy Can-Fite BioPharma stock | $2.16

Can-Fite BioPharma Ltd is a biotechnology business based in the US. Can-Fite BioPharma shares (CANF) are listed on the NYSE MKT and all prices are listed in US Dollars. Can-Fite BioPharma employs 8 staff and has a trailing 12-month revenue of around 0.00.

Can-Fite BioPharma stock price (NYSE MKT: CANF)

Use our graph to track the performance of CANF stocks over time.

Can-Fite BioPharma shares at a glance

• Key figures

Information last updated 2021-07-24.

Latest market close	$2.16
52-week range	$1.51 - $3.07
50-day moving average	$2.25
200-day moving average	$2.19
Wall St. target price	$6.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-5.01

Buy Can-Fite BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Can-Fite BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Can-Fite BioPharma Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Can-Fite BioPharma price performance over time

Historical closes compared with the close of $2.16 from 2021-05-28

1 week (2021-07-19)	N/A
1 month (2021-06-30)	-5.26%
3 months (2021-04-30)	-0.46%
6 months (2021-01-26)	N/A

1 year (2020-07-26)	N/A
2 years (2019-07-26)	N/A
3 years (2018-07-26)	N/A
5 years (2016-07-26)	N/A

Can-Fite BioPharma financials

Revenue TTM	$713,000
Gross profit TTM	$763,000
Return on assets TTM	-66.59%
Return on equity TTM	-197.23%
Profit margin	0%
Book value	$0.42
Market capitalisation	$38.1 million

TTM: trailing 12 months

Shorting Can-Fite BioPharma shares

There are currently 341,508 Can-Fite BioPharma shares held short by investors – that's known as Can-Fite BioPharma's "short interest". This figure is 13.6% up from 300,534 last month.

There are a few different ways that this level of interest in shorting Can-Fite BioPharma shares can be evaluated.

Can-Fite BioPharma's "short interest ratio" (SIR)

Can-Fite BioPharma's "short interest ratio" (SIR) is the quantity of Can-Fite BioPharma shares currently shorted divided by the average quantity of Can-Fite BioPharma shares traded daily (recently around 742408.69565217). Can-Fite BioPharma's SIR currently stands at 0.46. In other words for every 100,000 Can-Fite BioPharma shares traded daily on the market, roughly 460 shares are currently held short.

However Can-Fite BioPharma's short interest can also be evaluated against the total number of Can-Fite BioPharma shares, or, against the total number of tradable Can-Fite BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Can-Fite BioPharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Can-Fite BioPharma shares in existence, roughly 20 shares are currently held short) or 0.0207% of the tradable shares (for every 100,000 tradable Can-Fite BioPharma shares, roughly 21 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Can-Fite BioPharma.

Find out more about how you can short Can-Fite BioPharma stock.

Can-Fite BioPharma share dividends

We're not expecting Can-Fite BioPharma to pay a dividend over the next 12 months.

Have Can-Fite BioPharma's shares ever split?

Can-Fite BioPharma's shares were split on a 1:15 basis on 9 May 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can-Fite BioPharma shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Can-Fite BioPharma shares which in turn could have impacted Can-Fite BioPharma's share price.

Can-Fite BioPharma share price volatility

Over the last 12 months, Can-Fite BioPharma's shares have ranged in value from as little as $1.51 up to $3.07. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can-Fite BioPharma's is 1.5507. This would suggest that Can-Fite BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Can-Fite BioPharma overview

Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.

Frequently asked questions

What percentage of Can-Fite BioPharma is owned by insiders or institutions?
Currently 1.068% of Can-Fite BioPharma shares are held by insiders and 12.405% by institutions. How many people work for Can-Fite BioPharma?
Latest data suggests 8 work at Can-Fite BioPharma. When does the fiscal year end for Can-Fite BioPharma?
Can-Fite BioPharma's fiscal year ends in December. Where is Can-Fite BioPharma based?
Can-Fite BioPharma's address is: 10 Bareket Street, Petah Tikva, Israel, 4951778 What is Can-Fite BioPharma's ISIN number?
Can-Fite BioPharma's international securities identification number is: US13471N2018 What is Can-Fite BioPharma's CUSIP number?
Can-Fite BioPharma's Committee on Uniform Securities Identification Procedures number is: 13471N102